Mathieu Simon, M.D. Cellectis’ EVP & Chief Operating Officer, to Serve as Interim Chief Medical Officer

Published on October 04, 2017 in New York (N.Y.)

Back to all press releases

October 4, 2017 – New York (N.Y.) – Cellectis (Alternext: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that Mathieu Simon M.D. will act as Interim Chief Medical Officer, effective immediately. Dr. Simon is taking over the responsibilities of Loan Hoang-Sayag, Chief Medical Officer, who is leaving Cellectis to pursue other opportunities.

Dr. Mathieu Simon has served as Cellectis’ Executive Vice-President since 2012 and as Chief Operating Officer since 2013. Dr. Simon was Chief Executive Officer of former subsidiary Cellectis therapeutics and has been instrumental in the strategic and operational management of all therapeutic activities.

Download the PDF file